Purocenta (Para‑toluenesulfonamide) – NSCLC | DengYueMed

Purocenta Application Scope

Purocenta® is an injectable formulation of para‑toluenesulfonamide (PTS) designed for the intratumoral ablation of central airway tumors in NSCLC.

Characteristics

• Ingredients: PTS (para‑toluenesulfonamide) as the active pharmaceutical ingredient

• Properties:

  • Designed for intratumoral injection targeting solid tumors

  • Ablates tumor tissue in central airways, supporting local treatment

• Packaging Specification:

  • Supplied as sterile injectable vials

  • Specific volume per vial not yet publicly disclosed

• Storage: Store at controlled room temperature as per label (typically 2–25 °C)

• Expiry Date: As printed on each vial (common shelf life ~2–3 years, refer to packaging)

• Executive Standard: Manufactured under China NMPA Good Manufacturing Practice guidelines

• Approval Number:

  • First approved intratumoral cancer ablation therapy in China

  • Approval number available via NMPA

• Date of Revision:

  • Initial approval in 2024;

  • Label updates as per post‑marketing requirements

• Manufacturer: Gongwin Biopharm Co., Ltd., China

Guidelines for the Use of Purocenta

• Dosage and Administration:

  • Administer via intratumoral injection directly into the airway tumor under imaging guidance

  • Dosage and frequency are determined by tumor size and physician discretion

• Adverse Reactions:

  • Local reactions: discomfort, inflammation, minor bleeding

  • Systemic effects: uncommon; PTS metabolism is limited to local tissue

• Contraindications:

  • Allergy to PTS or formulation excipients

  • Not suitable for tumors inaccessible to direct injection

• Precautions:

  • Use sterile technique during injection

  • Monitor the airway for edema or hemorrhage after administration

Purocenta Interactions

• Drug Interactions: Not systemically absorbed; no known drug–drug interactions

Note:

• If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
• It is only for internal discussion among medical staff and does not serve as a basis for medication. For specific medication guidelines, please consult the attending physician.